Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report)’s stock price dropped 4.2% on Tuesday. The stock traded as low as $4.66 and last traded at $4.6760. Approximately 14,465 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 258,731 shares. The stock had previously closed at $4.88.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. Jefferies Financial Group raised shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 14th. Finally, Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $110.00.
Check Out Our Latest Analysis on IMMP
Prima BioMed Price Performance
Prima BioMed (NASDAQ:IMMP – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter. The firm had revenue of $3.68 million for the quarter.
About Prima BioMed
Prima BioMed Limited was an Australian biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.
Its lead development program was eftilagimod alpha, also known as IMP321, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support broader immune responses. Prima BioMed evaluated the therapy in combination with existing cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.
The company conducted clinical-development activities internationally, including in Australia, Europe and the United States.
Featured Articles
- Five stocks we like better than Prima BioMed
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
